Abstract
Hematospermia or hemospermia is traditionally defined as the presence of fresh or altered blood in semen. Several factors might cause hematospermia, including infectious, inflammatory, iatrogenic, traumatic, structural, neoplastic, vascular, and systemic factors. The main aim of evaluation is to identify significant or treatable underlying causes of hematospermia and to re-assure the patient if no causative factor is detected after full evaluation. This review aims novel management of hematospermia, including a detailed history, physical examination, appropriate laboratory investigations, and diagnostic imaging, based on underlying causes of hematospermia.
Keywords: Algorithms, hemospermia, semen
Main Points
Prostate biopsy has become the single most common cause of hematospermia in the modern urological era.
Urogenital infections are still the most common cause of hematospermia in men younger than 40 years of age.
The main aim of evaluation is to identify significant or treatable underlying causes of hematospermia and to re-assure the patient if no causative factor is detected after full evaluation.
The evaluation of hematospermia requires a detailed history, physical examination, and appropriate laboratory investigations and diagnostic imaging.
First step of treatment should be allaying the anxiety of the patients and their partners via giving sufficient information about hematospermia. Proper treatment of hematospermia that include specific and empiric treatments depends on the underlying pathology.
Introduction
Hematospermia or hemospermia is traditionally defined as the presence of fresh or altered blood in semen. It has been reported by physicians for many centuries from Hippocrates, Galen, Pare, Morgagni, Velpeau, Fournier to Guyon.1 Historically, majority of cases, as many as 70%, were diagnosed as functional and essential or idiopathic hematospermia. Functional causes included excessive sexual indulgence or intense sexual experiences, prolonged sexual abstinence, and interrupted coitus. Also, sudden emptying of a distended seminal vesicle causes hemorrhage “ex vacuo” was thought to be underlying cause of idiopathic hematospermia.2 Currently, with the use of advanced diagnostic tools, the exact cause of hematospermia can be found in most cases. There are several factors that might cause hematospermia, including infectious, inflammatory, iatrogenic, traumatic, structural, neoplastic, vascular, and systemic factors (Table 1).3
Table 1.
Etiology of Hematospermia, Modified From Suh et al.3
| Inflammation and Infections | Iatrogenic/Trauma |
|---|---|
| Hemorrhage ex vacuo | Prostate biopsy |
| Calculi of seminal vesicles, ejaculatory duct, prostate, urethra, bladder, or ureter | Prostatic injection, brachytherapy, cryotherapy, high-intensity focused ultrasound therapy |
| Prostatitis, seminal vesiculitis, urethritis, epididymo-orchitis | Pelvic external beam radiotherapy |
| Viral; HSV, CMV, HPV, Zika virus, HIV | External trauma to perineum genitalia or pelvis |
| Bacterial; C. trachomatis, N. gonorrhoeae, T. pallidum, | Coital or auto-erotic trauma |
| M. hominis, U. urealyticum, E. feacalis, etc. | Urethral catheterization/self-instrumentation |
| Parasitic; S. haematobium, E. granulosus | Ureteral/Urethral stents |
| Tumors | Vasectomy |
| Benign | Orchiectomy |
| Granulation, papillary adenoma, adenomatous polyps | Hemorrhoidal sclerotherapy |
| Condylomata accuminata | Drugs (aspirin, anticoagulants, and panitumumab) |
| Leiomyoma and adenomyosis of seminal vesicles | Ductal obstruction and cysts of accessory sexual glands |
| Tumors of spermatic cord and prostatic utricle | Ejaculatory duct obstruction |
| Angioleiomyoma of the testicle | Mullerian duct, prostatic, utricular, ejaculatory duct cysts |
| Malignant | Dilatation of seminal vesicles |
| Carcinoma of the prostate, testis, and seminal vesicle | Cyst and diverticula of seminal vesicles |
| Sarcoma of prostate and seminal vesicles | Urethral stricture |
| Intraductal carcinoma | Benign prostatic obstruction |
| Metastatic disease such as melanoma | Systemic factors |
| Rare tumors | Severe systemic hypertension |
| Vascular abnormalities | Cirrhosis of the liver, hyperuricemia |
| Abnormal veins in the prostatic urethra, prostatic telangiectasia | Amyloidosis of seminal vesicles |
| Hemangioma of urethra and spermatic cord | Scurvy |
| Arteriovenous/vascular malformation Semino-vesico-venous and vaso-venous fistulas | Hematological disorders (Hemophilia, von Willebrand disease, leukemia, and lymphoma) |
Hematospermia is thought to originate from the prostate gland, ejaculatory duct, seminal vesicle, vas deferens, epididymis, testis, urethra, or urinary bladder as the causative lesions in different studies.4 Currently, iatrogenic trauma is the most common cause of hematospermia. Because prostate biopsies have been performed more frequently in older ages, prostate biopsy has become the single most common cause of hematospermia in the modern urological era.5,6 However, urogenital infections are still the most common cause of hematospermia in men younger than 40 years of age.7 Inflammatory processes causing mucosal irritation, hyperemia, and edema of the accessory sexual glands and their ducts may lead to bleeding and the clinical manifestation of hematospermia. This inflammation can be a result of traumatic, chemical, or infectious causes.8 Ductal obstruction and cyst formation of accessory sexual gland and systemic factors are other causes of hematospermia. The responsible mechanism in cases with obstruction and cyst is thought to be associated with dilatation and distention, resulting in rupture of mucosal blood vessels.9 The most common cause of systemic factor that is associated with hematospermia is an acquired anticoagulable state secondary to drugs.10 Hematospermia is rarely associated with any urological malignancies, and it can be the sole symptom in men with urogenital cancer.11 It has been postulated that fragile aberrant vessels produced by tumor angiogenic stimuli might contribute to the situation.12
The exact incidence of hematospermia remains unknown and because of its self-limiting nature, most men do not observe their ejaculate, and in cases of men who notice it, some patients are hesitant to apply for medical care for this symptom.13 It is thought to be a relatively rare condition, and it is a symptom accounting for about 1% of urological referrals, and only a busy urologist may see more than one case per month.2,14 In the majority, hematospermia is a benign and self-limiting symptom. However, it is a condition that can be a source of great anxiety among patients and their partners who are often fearful of cancer or venereal disease. Most patients typically visit their primary-care physician after a single episode of hematospermia, being concerned about this serious condition.15
The main aim of evaluation is to identify significant or treatable underlying causes of hematospermia and to re-assure the patient if no causative factor is detected after a full evaluation.16 The evaluation of hematospermia requires a detailed history, physical examination, and appropriate laboratory investigations and diagnostic imaging.
History
Detailed history is essential for evaluation of hematospermia. The features of the hematospermia, including color, amount, timing (coitus and/or masturbation), frequency, and duration, should be ascertained. It is also important to ask about relevant concomitant symptoms (Table 2).17“Hematospermia may be accompanied by other symptoms, but if hematospermia is the only symptom, it is defined as monosymptomatic hematospermia. Hematospermia, when recurrent, is defined as recurrent hematospermia. Also, if it continues despite the conservative or definitive treatment, it is defined as persistent hematospermia.”10 It is important to obtain a detailed medical history, including systemic diseases, surgical history, and the use of drugs. The patient is questioned to whether there was any external trauma in the urogenital region. Travel history to places with schistosomiasis or tuberculosis endemic areas should also be investigated.8
Table 2.
Symptoms That Accompany Hematospermia and Possible Causes
| Symptom | Underlying Pathology |
|---|---|
| Urethral discharge | Urethritis, prostatitis |
| Dysuria | Cystitis, urethritis, prostatitis |
| Hematuria | Cystitis, urethritis, prostatitis, prostatic or urethral polyps, bladder or prostate cancer |
| Lower urinary tract symptoms | Cystitis, urethritis, prostatitis, primary or secondary involvement of the bladder or bladder outlet |
| Pelvic/perineal pain/discomfort | Cystitis, urethritis, prostatitis, obstruction of ejaculatory duct |
| Painful ejaculation - Orgasmalgia | Prostatitis, obstruction of ejaculatory duct |
| Low ejaculate volume, infertility | Obstruction of ejaculatory duct |
| Testicular pain and swelling | Epididymal or testicular infections or tumor |
| Systemic symptoms (weight loss, night sweats, chills, fewer, bone pain, etc.) | Infectious diseases, genitourinary cancer |
| Overt mucosal bleeding, bleeding into the skin | Bleeding and clotting disorders, leukemia, lymphoma, drugs |
Physical Examination
Similar to history, complete physical examination, including systemic, genital, and rectal examination, is principal for evaluation of hematospermia. The patient’s body temperature and blood pressure should be recorded, and the abdomen should be carefully examined to exclude enlargement of liver or spleen or the presence of pelvic masses. The groin, perineum, and external genitalia examination should be examined for any skin lesions, presence of hypospadias, and nodularity or induration on testis and spermatic cord. Digital rectal examination is performed to eliminate the possibility of prostate and seminal vesicle infective disorders, cysts, and pathological masses. After digital rectal examination, urethral meatus should be re-examined for presence of bloody discharge.18,19
Laboratory Tests
Laboratory tests for evaluation of hematospermia include urine analysis and bacterial culture, urethral swab, Meares-Stamey four-glass test, semen analysis and culture, blood cell count, serum biochemical and coagulation parameters, and serum prostate-specific antigen levels. These tests should be tailored to individual patients.12,18
Urine analysis and culture-antibiogram are recommended for all patients with hematospermia, as these tests are low-cost and help confirm the presence of infection and hematuria in patients.20,21 However, traditionally the rate of positive culture results is low but current laboratory techniques can identify more microorganisms. The presence of hematuria is a risk factor for more serious underlying pathology. Therefore, if it occurs, a complete evaluation for hematuria should be performed.21
If a sterile pyuria is detected then further investigations are required to exclude chronic inflammatory disorder, such as chronic non-bacterial prostatitis, tuberculosis, schistosomiasis, and viral infections. Urethral swabs/cultures, Meares-Stamey four-glass test, semen cultures, and viral serology are tests that are used for this purpose.16 Urethral swab/cultures for N. gonorrhoeae and C. trachomatis should also be performed when sexually transmitted diseases are suspected or urethritis is accompanied with hematospermia.3,16 Semen analysis is helpful to distinguish between hematospermia and pseudo-hematospermia. It should also be performed when hematospermia is associated with low ejaculate volume and/or infertility.22
Hematospermia is related to an increased risk of prostate cancer. Because of this, serum prostate-specific antigen level measurement is obligatory in patients older than 40 years of age and/or when hematospermia is recurrent.11 Coagulation studies are recommended for patients with hematological disease, patients using any anticoagulant/antifibrinolytic drugs, and patients with recurrent hematospermia, especially >2 months, due to this situation are associated with coagulation disorders.14 In addition, complete blood count, creatinine and electrolytes, uric acid, and liver function tests should be performed if history and/or examination suggests chronic disorders.12
Diagnostic Imaging and Endoscopy
Vaso-Vesiculography
Vaso-vesiculography is almost never used today in the diagnostic evaluation of hematospermia. This invasive technique provides little data to detect the etiology of hematospermia. Also, it requires x-ray and may cause serious side effects, such as vasal injury and stricture.1,23
Computerized Tomography
Computerized tomography has limited value in the etiologic determination of hematospermia owing to its x-ray necessity, lack of soft-tissue contrast, and limitations in the evaluation of smallcaliber structures, such as the ejaculatory duct or vas deferens and in the evaluation of the internal structure of the seminal vesicle and prostate gland.1,24
Scrotal Ultrasonography
Maheshkumar et al25 reported persistent hematospermia as presenting symptom of testicular cancer in a patient who did not have any associated symptoms and physical examination findings. Thus, scrotal ultrasonography should be performed in patients with persistent hematospermia, or in case of any associated symptom, in order to rule out testicular pathology as an underlying cause of hematospermia.10,25
Transrectal Ultrasonography
Many authors have reported that transrectal ultrasonography TRUS is a safe, simple, easily accessible, cost-effective, radiation free, and relatively noninvasive imaging modality that can clearly image seminal vesicles, ejaculatory ducts, and the prostate objectively.4 Its accurate diagnostic rate in patients with recurrent or persistent hematospermia is up to 95%.26,27 However, TRUS has some limitations, such as images obtained with ultrasonography are subject to observer variation, spatial resolution, and soft-tissue contrast may not permit complete evaluation of the ejaculatory duct and seminal vesicle, and therefore might not show the origin of bleeding, and as a result of this, it has a false positive/negative rate of approximately 50%. Thus, it has been suggested that TRUS should not be considered definitive but as primary screening modality for patients with recurrent or persistent haematospermia.27,28 TRUS can provide definitive diagnosis if a lesion is detected or confirmed by means of TRUS-guided seminal vesicle aspiration, prostate and seminal vesicle biopsy, and semino-vesiculography. It can also be used as a guide for treatment of hematospermia, such as TRUS-guided cyst aspiration, TRUS-guided laser incision of cyst, TRUSguided balloon dilation of ejaculatory duct in an antegrade fashion, and transurethral resection of ejaculatory duct (TURED) with TRUS-guided chromotubation.24,29
Magnetic Resonance Imaging
Magnetic resonance imaging, owing to its excellent soft-tissue contrast, multiplanar capabilities, independence from the operator, and lack of ionization radiation, plays an important role as a noninvasive imaging modality in the diagnostic workup of recurrent or persistent hematospermia.30 Although costly, current gold standard for imaging of structural and inflammatory/infective changes in accessory sex gland and their ducts is MRI. In the presence of suspected cancer, it should include dynamic contrast imaging that provides additional information regarding tissue perfusion. In addition, MRI angiography provides further information for localizing bleeding.24,30 Magnetic resonance imaging has at least 80% diagnostic performance in patients with recurrent or persistent hematospermia. Endorectal phased-array coil is superior to external phased-array coil for evaluation of the prostatic region, but it causes discomfort to the patient. However, Sosna et al31 showed the image quality at the external coil at 3.0 T to be comparable with the endorectal coil at 1.5 T.
In a large series of patients with recurrent or persistent hematospermia, Li et al28 reported that there is no significant difference in the positive rate of abnormal imaging between MRI and TRUS (86.3% vs. 84.3%, P >.05), while MRI provides more precise causative information, particularly regarding ejaculatory duct obstruction and hemorrhage location, than TRUS. According to American College of Radiology, MRI is indicated when TRUS results are negative or inconclusive (Tables 3 and 4).24
Table 3.
ACR Appropriateness Criteria® on Hematospermia; Patients Under 40 Years of Age with Transient and Monosymptomatic Hematospermia (Modified from Expert Panel on Urologic Imaging, 2017).24
| Radiologic Procedure | Appropriateness Rating | Relative Radiation Level | Effective Dose Estimate Range(mSv) |
|---|---|---|---|
| Transrectal ultrasound | 3 | 0 | 0 |
| MRI pelvis | |||
| without iv contrast | 3 | 0 | 0 |
| without and with iv contrast | 3 | 0 | 0 |
| CT pelvis | |||
| without iv contrast | 1 | 3 | 1–10 |
| with iv contrast | 1 | 3 | 1–10 |
| without and with iv contrast | 1 | 4 | 10–30 |
| Arteriographypelvis | 1 | 4 | 10–30 |
Note: ACR: American College of Radiology; MRI: magnetic resonance imaging; CT: computerized tomography; iv: intravenous.
Rating scale: 1, 2, 3 = usually not appropriate; 4, 5, 6 = may be appropriate; 7, 8, 9 = usually appropriate.
Table 4.
ACR Appropriateness Criteria® on Hematospermia; Patients Over 40 Years of Age, or Any Age with Recurrent Hematospermia, or Hematospermia Accompanied by Associated Symptoms or Signs of Disease (Modified From Expert Panel on Urologic Imaging, 2017).24
| Radiologic Procedure | Appropriateness Rating | Relative Radiation Level | Effective Dose Estimate Range(mSv) |
|---|---|---|---|
| Transrectal ultrasound | 8 | 0 | 0 |
| MRI pelvis | |||
| ‰without iv contrast | 7 | 0 | 0 |
| ‰without and with iv contrast | 8 | 0 | 0 |
| CT pelvis | |||
| ‰without iv contrast | 1 | 3 | 1–10 |
| ‰with iv contrast | 2 | 3 | 1–10 |
| ‰without and with iv contrast | 1 | 4 | 10–30 |
| ‰Arteriography pelvis | 2 | 4 | 10–30 |
ACR, American College of Radiology; CT, computerized tomography; iv, intravenous; MRI, magnetic resonance imaging.
Rating scale: 1, 2, 3 = usually not appropriate; 4, 5, 6 = may be appropriate; 7, 8, 9 = usually appropriate.
Pelvic Angiography
In the literature, pelvic angiography has been rarely reported to be useful for diagnosis of patients with persistent massive hematospermia and hematuria due to vascular masses, such as prostatic hemangioma, arteriovenous malformation, and varices. If an arterial source of hemorrhage is identified, transcatheter arterial embolization or electrofulguration can be performed during the same session as well.32
Urethrocystoscopy
When hematospermia is accompanied by hematuria in elderly patients or all attempts to diagnose the disease fails, in high risk patients with recurrent or persistent hematospermia, rigid or flexible urethrocystoscopy should be considered. It allows direct vision of urethra, prostate, bladder neck, and bladder and their pathologic conditions. Concurrent massage of the prostate and seminal vesicles may be useful for localizing bleeding. Due to its very poor diagnostic performance, urethrocystoscopy is not recommended routinely for diagnostic workup of hematospermia, as well as renal tract ultrasound and intravenous urography.33
Transurethral Seminal Vesiculoscopy
Transurethral seminal vesiculoscopy (TSV) is another endoscopic technique that can directly visualize etiological lesions in the ejaculatory duct and seminal vesicles with high sensitivity and specificity. A definite diagnosis rate of 93.1% was reported in the first large-scale report of patients with recurrent or persistent hematospermia.34 In a prospective study, Xing et al26 compared TSV and TRUS for the diagnosis of persistent hematospermia. They reported that overall diagnostic yield of TSV was significantly superior to that of TRUS (74.5% vs. 45.3%, P < .001) and the diagnostic yield of combining TSV and TRUS was significantly higher than that of each modality alone (both P < .001). In addition, TSV is not only a diagnostic but also a treatment tool for ejaculatory duct and seminal vesicle pathologies. However, even though it is a minimally invasive procedure that requires anesthesia, TSV is currently not standardized, failures still occur, long-term safety is uncertain, and can lead to complications, such as epididymitis, ejaculation abnormality, and injury of the seminal vesicle and rectum.23,34
Treatment
First step of treatment should be allaying the anxiety of the patients and their partners via giving sufficient information about hematospermia. Due to natural history of hematospermia, reassurance and follow-up without any treatment will be adequate for many patients. In a prospective study investigating natural history of hematospermia in patients who underwent watchful waiting without any empirical treatment, Furuya et al9 reported that the persistence rates of hematospermia were 57.7% at 1 month, 34.2% at 3 months, 23.3% at 6 months, 12.5% at 1 year, and 7.6% at 2 years. Iatrogenic causes of hematospermia usually resolve spontaneously within approximately 10 ejaculations or on an average 11 days, but it can continue for up to 2 months.5,6
Proper treatment of hematospermia that include specific and empiric treatments depends on the underlying pathology. If urogenital infection is affirmed, the treatment of appropriate antibiotic, antiparasitic, or antiviral agents is indicated on the basis of the sensitivity of the cultured organism.20 Also, systemic conditions, if any, should be treated appropriately.
If infection is suspected, but no pathological findings are determined, empiric treatment is suitable. Antibiotics should be capable of penetrating the prostate-blood barrier (e.g., fluoroquinolones, tetracyclines, macrolides, trimethoprim-sulfamethoxazole, and metronidazole) and non-steroidal anti-inflammatory drugs (e.g., ibuprofen and celocoxib). In a large, but non-controlled and retrospective study, Zargooshi et al.15 reported that in 94.9% of patients, hematospermia did not recur after empirical treatment (ciprofloxacin plus celocoxib). Other empiric treatments contain antifibrinolytic, antiandrogenic, and estrogenic agents, such as aminocaproic acid,35 finasteride,36 and ethinyl estradiol.37 These agents should only be used in selected patients with persistent hematospermia, as there is insufficient evidence on the use of such agents.
Specific surgical treatment is given, if it is required, when vascular anomalies, polyps, calcification, cysts, or other pathological conditions are detected. Urethroscope-guided electroexcision and/or fulguration of polyps and vascular anormalies in posterior urethra,29 direct drug injection to seminal vesicles guided by TRUS,38 TRUS-guided cyst aspiration with or without sclerotherapy,39 TRUS-guided transurethral laser incision of cyst,40 transurethral unroofing or laparoscopic management of seminal vesicle cysts,41 TURED with or without TRUS-guided choromotubation,42 TRUS and fluoroscopic assisted transurethral incision of ejaculatory ducts,43 urethroscopy and TRUS or CT/MRI-guided recanalization and dilatation of ejaculatory duct,22,44 TSV-guided incision of obstructed ejaculatory duct, coagulate hemorrhagic mucosa, and fragment stones in the ejaculatory duct or seminal vesicle by using electric or laser energy systems7,45 are methods that can be performed for this purpose.
In conclusion, to address how the novel algorithm in the management of hematospermia should be, the first step is to rule out pseudo-hematospermia, which could be because of bleeding from sexual partner source, hematuria, urethral bleeding, and melanospermia.19 If in doubt, a “condom test” should be performed, where the semen is collected and then checked for blood.20 Once true hematospermia has been affirmed, the diagnostic process should be initiated with a clinical history and physical examination. Afterward, 3 key factors help guide further evaluation (Figure 1): age, duration of hematospermia, and presence of concomitant symptoms or risk factors since recurrent or persistent hemospermia may indicate a more serious underlying pathology, especially in patients over 40 years of age.17 However, the evidence basis for the investigation and management of haematospermia remains lacking.13,33
Figure 1.
Novel Algorithm for the Management of Hematospermia.
Footnotes
Peer-review: This manuscript was prepared by the invitation of the Editorial Board and its scientific evaluation was carried out by the Editorial Board.
Author Contributions: Concept – O.E., S.Ç.; Design – O.E., S.Ç., E.A.; Supervision – O.E., S.Ç., E.A.; Resources – O.E.; Materials – O.E.; Data Collection and/or Processing – O.E.; Analysis and/or Interpretation – O.E.; Literature Search – O.E., S.Ç., E.A.; Writing Manuscript – O.E., S.Ç.; Critical Review – S.Ç., E.A.; Other – O.E., S.Ç., E.A.
Declaration of Interests: The authors have no conflicts of interest to declare.
References
- 1.Torigian DA, Ramchandani P. Hematospermia: imaging findings. Abdom Imaging. 2007;32(1):29-49. 10.1007/s00261-006-9013-3 [DOI] [PubMed] [Google Scholar]
- 2.Ganabathi K, Chadwick D, Feneley RC, Gingell JC. Haemospermia. Br J Urol. 1992;69(3):225-230. (doi: 10.1111/j.1464-410x.1992.tb15517.x) [DOI] [PubMed] [Google Scholar]
- 3.Suh Y, Gandhi J, Joshi G, et al. Etiologic classification, evaluation, and management of hematospermia. Transl Androl Urol. 2017;6(5): 959-972. (doi: 10.21037/tau.2017.06.01) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zhao H, Luo J, Wang D, et al. The value of transrectal ultrasound in the diagnosis of hematospermia in a large cohort of patients. J Androl. 2012;33(5):897-903. (doi: 10.2164/jandrol.111.013318) [DOI] [PubMed] [Google Scholar]
- 5.Manoharan M, Ayyathurai R, Nieder AM, Soloway MS. Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study. Prostate Cancer Prostatic Dis. 2007;10(3):283-287. (doi: 10.1038/sj.pcan.4500955) [DOI] [PubMed] [Google Scholar]
- 6.Efesoy O, Bozlu M, Çayan S, Akbay E. Complications of transrectal ultrasound-guided 12-core prostate biopsy: a single center experience with 2049 patients. Turk J Urol. 2013;39(1):6-11. (doi: 10.5152/tud.2013.002) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Liao LG, Li YF, Zhang Y, et al. Etiology of 305 cases of refractory hematospermia and therapeutic options by emerging endoscopic technology. Sci Rep. 2019;9(1):5018. (doi: 10.1038/s41598-019-41123-2) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Szlauer R, Jungwirth A. Haematospermia: diagnosis and treatment. Andrologia. 2008;40(2):120-124. (doi: 10.1111/j.1439-0272.2007.00821.x) [DOI] [PubMed] [Google Scholar]
- 9.Furuya S, Masumori N, Takayanagi A. Natural history of hematospermia in 189 Japanese men. Int J Urol. 2016;23(11):934-940. (doi: 10.1111/iju.13176) [DOI] [PubMed] [Google Scholar]
- 10.Efesoy O, Çayan S, Aşcı R, Orhan İ, Yaman Ö. Hematospermia is rarely related to genitourinary cancer: lessons learned from 15 years of experience with 342 cases. Int J Impot Res. 2021;33(6):627-633. (doi: 10.1038/s41443-020-0330-9) [DOI] [PubMed] [Google Scholar]
- 11.Han M, Brannigan RE, Antenor JA, Roehl KA, Catalona WJ. Association of hemospermia with prostate cancer. J Urol. 2004; 172(6 Pt 1):2189-2192. (doi: 10.1097/01.ju.0000144565.76243.b1) [DOI] [PubMed] [Google Scholar]
- 12.Ahmad I, Krishna NS. Hemospermia. J Urol. 2007;177(5):1613-1618. (doi: 10.1016/j.juro.2007.01.004) [DOI] [PubMed] [Google Scholar]
- 13.Parnham A, Serefoglu EC. Retrograde ejaculation, painful ejaculation and hematospermia. Transl Androl Urol. 2016;5(4):592-601. (doi: 10.21037/tau.2016.06.05) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Polito M, Giannubilo W, d’Anzeo G, Muzzonigro G. Hematospermia: diagnosis and treatment. Arch Ital Urol Androl. 2006; 78(2):82-85. [PubMed] [Google Scholar]
- 15.Zargooshi J, Nourizad S, Vaziri S, et al. Hemospermia: long-term outcome in 165 patients. Int J Impot Res. 2014;26(3):83-86. (doi: 10.1038/ijir.2013.40) [DOI] [PubMed] [Google Scholar]
- 16.Kumar P, Kapoor S, Nargund V. Haematospermia: a systematic review. Ann R Coll Surg Engl. 2006;88(4):339-342. (doi: 10.1308/003588406X114749) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Stefanovic KB, Gregg PC, Soung M. Evaluation and treatment of hematospermia. Am Fam Phys. 2009;80(12):1421-1427. [PubMed] [Google Scholar]
- 18.Munkel witz R, Krasnokutsky S, Lie J, Shah SM, Bayshtok J, Khan SA. Current perspectives on hematospermia: a review. J Androl. 1997;18(1):6-14. [PubMed] [Google Scholar]
- 19.Akhter W, Khan F, Chinegwundoh F. Should every patient with hematospermia be investigated? A critical review. Cent Eur J Urol. 2013;66(1):79-82. (doi: 10.5173/ceju.2013.01.art25) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Fuse H, Komiya A, Nozaki T, Watanabe A. Hematospermia: etiology, diagnosis, and treatment. Reprod Med Biol. 2011; 10(3):153-159. (doi: 10.1007/s12522-011-0087-4) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Leocádio DE, Stein BS. Hematospermia: etiological and management considerations. Int Urol Nephrol. 2009;41(1):77-83. (doi: 10.1007/s11255-008-9409-9) [DOI] [PubMed] [Google Scholar]
- 22.Jarow JP, Zagoria RJ. Antegrade ejaculatory duct recanalization and dilation. Urology. 1995;46(5):743-746. (doi: 10.1016/S0090-4295(99)80316-1) [DOI] [PubMed] [Google Scholar]
- 23.Chen R, Wang L, Sheng X, et al. Transurethral seminal vesiculoscopy for recurrent hemospermia: experience from 419 cases. Asian J Androl. 2018;20(5):438-441. (doi: 10.4103/aja.aja_76_17) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Expert Panel on Urologic Imaging, Hosseinzadeh K, Oto A, et al. ACR appropriateness Criteria® hematospermia. J Am Coll Radiol. 2017;14(5S):S154-S159. (doi: 10.1016/j.jacr.2017.02.023) [DOI] [PubMed] [Google Scholar]
- 25.Maheshkumar P, Otite U, Gordon S, Berney DM, Nargund VH. Testicular tumor presenting as hematospermia. J Urol. 2001; 165(1):188. (doi: 10.1097/00005392-200101000-00050) [DOI] [PubMed] [Google Scholar]
- 26.Xing C, Zhou X, Xin L, et al. Prospective trial comparing transrectal ultrasonography and transurethral seminal vesiculoscopy for persistent hematospermia. Int J Urol. 2012;19(5):437-442. (doi: 10.1111/j.1442-2042.2011.02952.x) [DOI] [PubMed] [Google Scholar]
- 27.Raviv G, Laufer M, Miki H. Hematospermia--the added value of transrectal ultrasound to clinical evaluation: is transrectal ultrasound necessary for evaluation of hematospermia? Clin Imaging. 2013;37(5):913-916. (doi: 10.1016/j.clinimag.2013.05.007) [DOI] [PubMed] [Google Scholar]
- 28.Li BJ, Zhang C, Li K, et al. Clinical analysis of the characterization of magnetic resonance imaging in 102 cases of refractory haematospermia. Andrology. 2013;1(6):948-956. (doi: 10.1111/j.2047-2927.2013.00132.x) [DOI] [PubMed] [Google Scholar]
- 29.Avellino GJ, Lipshultz LI, Sigman M, Hwang K. Transurethral resection of the ejaculatory ducts: etiology of obstruction and surgical treatment options. Fertil Steril. 2019;111(3):427-443. (doi: 10.1016/j.fertnstert.2019.01.001) [DOI] [PubMed] [Google Scholar]
- 30.Mittal PK, Camacho JC, Sahani DV, et al. Hematospermia evaluation at MR imaging. RadioGraphics. 2016;36(5):1373-1389. (doi: 10.1148/rg.2016150195) [DOI] [PubMed] [Google Scholar]
- 31.Sosna J, Pedrosa I, Dewolf WC, Mahallati H, Lenkinski RE, Rofsky NM. MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. Acad Radiol. 2004;11(8):857-862. (doi: 10.1016/j.acra.2004.04.013) [DOI] [PubMed] [Google Scholar]
- 32.Wang LJ, Tsui KH, Wong YC, Huang ST, Chang PL. Arterial bleeding in patients with intractable hematospermia and concomitant hematuria: a preliminary report. Urology. 2006;68(5):938-941. (doi: 10.1016/j.urology.2006.06.015) [DOI] [PubMed] [Google Scholar]
- 33.Ng YH, Seeley JP, Smith G. Haematospermia as a presenting symptom: outcomes of investigation in 300 men. Surgeon. 2013;11(1):35-38. (doi: 10.1016/j.surge.2012.04.004) [DOI] [PubMed] [Google Scholar]
- 34.Liu ZY, Sun YH, Xu CL, et al. Transurethral seminal vesiculoscopy in the diagnosis and treatment of persistent or recurrent hemospermia: a single-institution experience. Asian J Androl. 2009;11(5):566-570. (doi: 10.1038/aja.2009.47) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Rastinehad AR, Ost MC, VanderBrink BA, Siegel DN, Kavoussi LR. Persistent prostatic hematuria. Nat Clin Pract Urol. 2008;5(3):159-165. (doi: 10.1038/ncpuro1044) [DOI] [PubMed] [Google Scholar]
- 36.Badawy AA, Abdelhafez AA, Abuzeid AM. Finasteride for treatment of refractory hemospermia: prospective placebo-controlled study. Int Urol Nephrol. 2012;44(2):371-375. (doi: 10.1007/s11255-011-0057-0) [DOI] [PubMed] [Google Scholar]
- 37.Huggins C, Mcdonald DF. Chronic hemospermia; Its origin and treatment with estrogen. J Clin Endocrinol Metab. 1945;5(5): 226-231. (doi: 10.1210/jcem-5-5-226) [DOI] [Google Scholar]
- 38.Fuse H, Sumiya H, Ishii H, Shimazaki J. Treatment of hemospermia caused by dilated seminal vesicles by direct drug injection guided by ultrasonography. J Urol. 1988;140(5):991-992. (doi: 10.1016/s0022-5347(17)41907-0) [DOI] [PubMed] [Google Scholar]
- 39.Saito S. Transrectal ultrasound-guided puncture, drainage, and minocycline hydrochloride sclerotherapy for the symptomatic prostatic cyst. J Endourol. 2002;16(9):693-695. (doi: 10.1089/089277902761403087) [DOI] [PubMed] [Google Scholar]
- 40.Halpern EJ, Hirsch IH. Sonographically guided transurethral laser incision of a Müllerian duct cyst for treatment of ejaculatory duct obstruction. AJR Am J Roentgenol. 2000;175(3):777-778. (doi: 10.2214/ajr.175.3.1750777) [DOI] [PubMed] [Google Scholar]
- 41.Wang MS, Li BJ, Huang ZM, et al. Transurethral endoscopic treatment of seminal vesicle cysts (report of seven cases). Int Urol Nephrol. 2015;47(5):717-721. (doi: 10.1007/s11255-015-0944-x) [DOI] [PubMed] [Google Scholar]
- 42.Mekhaimar A, Goble M, Brunckhorst O, et al. A systematic review of transurethral resection of ejaculatory ducts for the management of ejaculatory duct obstruction. Turk J Urol. 2020;46(5):335-347. (doi: 10.5152/tud.2020.20228) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Manohar T, Ganpule A, Desai M. Transrectal ultrasound- and fluor oscop ic-as siste d transurethral incision of ejaculatory ducts: a problem-solving approach to nonmalignant hematospermia due to ejaculatory duct obstruction. J Endourol. 2008;22(7):1531-1535. (doi: 10.1089/end.2007.0415) [DOI] [PubMed] [Google Scholar]
- 44.Kayser O, Osmonov D, Harde J, Girolami G, Wedel T, Schäfer P. Less invasive causal treatment of ejaculatory duct obstruction by balloon dilation: a case report, literature review and suggestion of a CT- or MRI-guided intervention. Ger Med Sci. 2012;10:Doc06. (doi: 10.3205/000157) [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Oh TH, Seo IY. Endoscopic treatment for persistent hematospermia: a novel technique using a holmium laser. Scand J Surg. 2016;105(3):174-177. (doi: 10.1177/1457496915613647) [DOI] [PubMed] [Google Scholar]

Content of this journal is
licensed under a 